Last checked at 19 May 2016 10:17
Hikma Pharmaceuticals PLC - Vesting of 2013 LTIP
LONDON, 19 May 2016: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") announces that the following Directors and Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 17 May 2016 under the 2005 Long Term Incentive Plan ("LTIP") which was completed on 19 May 2016. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is £nil. As indicated in the table below, certain PDMRs have made disposals.
In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over Hikma's Ordinary Shares of 10p each ("Shares") as detailed below.
PDMR | Type of Transaction | Shares Acquired under LTIP | Date | Price | Shares Disposed | Remaining Holding | |
Said Darwazah | Vesting of LTIP 2013 | 88,383 (0.04% ISC) | 19 May 2016 | N/A | Nil | 13,265,884* (5.54% ISC) | |
Mazen Darwazah | Vesting of LTIP 2013 | 45,924 (0.02% ISC) | 19 May 2016 | N/A | Nil | 7,256,131* (3.03% ISC) | |
Bassam Kanaan
| Vesting of LTIP 2013 & Disposal | 34,660 (0.01% ISC) | 19 May 2016 | £22.42 | 34,660 | 418,658 (0.19% ISC) | |
Michael Raya
| Vesting of LTIP 2013 & Disposal | 32,927 (0.01% ISC) | 19 May 2016 | £22.42 | 19,047 | 133,840 (0.06% ISC) | |
Riad Mishlawi | Vesting of LTIP 2013 | 19,063 (0.01% ISC)
| 19 May 2016 | N/A | Nil | 119,090 (0.05% ISC) | |
Khalid Nabilsi | Vesting of LTIP 2013 | 19,063 (0.01% ISC)
| 19 May 2016 | N/A | Nil | 221,921 (0.09% ISC) | |
Majda Labadi | Vesting of LTIP 2013 | 14,848 (0.01% ISC)
| 19 May 2016 | N/A | Nil | 187,431 (0.08% ISC) | |
"ISC" = Issued Share Capital of Hikma which is 239,385,501 Shares following the release of the LTIP 2013.
* Said Darwazah has a direct interest in Hikma of 745,383 Shares and an effective interest in Hikma through his interest in Darhold Limited of 12,520,501 Shares. Mazen Darwazah has a direct interest in Hikma of 952,965 Shares and an effective interest in Hikma through his interest in Darhold Limited of 6,303,166 Shares.
|
| ||||||
- ENDS -
Enquiries
Peter Speirs +44 20 7399 2760
Company Secretary, Hikma Pharmaceuticals PLC
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.